Pharmaceutical Technology Europe, Jun 1, 2011 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Jun 1, 2011
Editor's Comment
Celebration And Cinema
By Rich Whitworth
It was a mixed crowd hosted by Dusseldorf in the middle of May.
Special Feature
The Rising Uptake Of Immediate Release And ODT Formulations
By Jan Bebber
BASF's Jan Bebber explains why immediate-release formulations boost drug efficacy and aid patient compliance.
The Influence Of Superdisintegrants On Immediate Release
By John Fitzpatrick
When it comes to immediate-release tablet formulations, the choice of disintegrant can have a significant effect on the rate and extent of drug dissolution.
Table Testing Techniques
By Jo Smewing
The rising popularity of fast dissolving, immediate-release dosage forms can be attributed to their convenience and ease of administration.
Peer-Reviewed Research
A Comparison of Three Extrusion Systems (Part II)
The authors compare three systems of single-screw extrusion using binary formulations for their suitability for producing pellets of various formulations and under various spheronization conditions.
Inhibiting the Precipitation of Poorly Water-Soluble Drugs from Labrasol Formulations
The study results suggested that Pluronic F127 might be a potent inhibitor of drug precipitation for Labrasol formulations.
New Annex 11: Enabling Innovation
By Markus Roemer
In January 2011, the European Medicines Agency (EMA) announced the new revision of EudraLex Volume 4 (GMP) - Annex 11 'Computerised Systems', and the consequential amendment of EudraLex Volume 4 - Chapter 4 ?Documentation?.
Annex 11: Progress in EU Computer Systems Guidelines
By Orlando Lòpez
In January 2011, a new version of Annex 11 was released by the European Commission along with a revision of Chapter 4 of its GMP on documentation to reflect the actualities of electronic record keeping, all of which come into full effect in June 2011.
Industry Insider
The EMA And EU Expansion
By Nathan Jessop
The greatest challenge faced by the EMA is the continuing expansion of the EU.
Disposables Advisor
The Single-Use Technology World Tour
By Jerold Martin
Regions around the world are starting to follow the US trend in disposables and are working to solve common challenges.
Optimising High-Potency Manufacture
Effective containment in API and drug-product manufacturing encompasses a variety of process, equipment, and operational issues.
Microdosing for better medicines


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here